EVOTEC Aktie
WKN: 566480 / ISIN: DE0005664809
21.07.2025 11:25:04
|
EQS-Adhoc: Evotec SE adjusts revenue guidance while confirming profit guidance
EQS-Ad-hoc: EVOTEC SE / Key word(s): Change in Forecast Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec SE adjusts revenue guidance while confirming profit guidance Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged. For the current fiscal year, the Company expects Group revenues in the range of R&D expenditures are expected in a range of €40 – 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA is expected to reach €30–50m (unchanged; 2024: € 22.6 m). The primary reasons for the refined guidance are a change in the revenue mix and significant cost savings in excess of initial targets set during the Priority Reset. Technology licensing – a key pillar of Evotec’s strategic repositioning – is expected to make a stronger contribution. At the same time, the Shared R&D base business is expected to continue to operate in a challenging market environment in the second half of 2025. Group revenues were below expectations in H1 2025, while adjusted EBITDA was broadly in line with expectations. Actions are underway to transform the business towards sustainable profitable growth.
– End of the ad hoc release – Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com End of Inside Information
21-Jul-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | info@evotec.com |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 2172326 |
End of Announcement | EQS News Service |
|
2172326 21-Jul-2025 CET/CEST

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu EVOTEC SEmehr Nachrichten
22.07.25 |
XETRA-Handel TecDAX sackt zum Ende des Dienstagshandels ab (finanzen.at) | |
22.07.25 |
Verluste in Frankfurt: TecDAX fällt am Nachmittag zurück (finanzen.at) | |
22.07.25 |
MDAX aktuell: So steht der MDAX nachmittags (finanzen.at) | |
22.07.25 |
ANALYSE-FLASH: Deutsche Bank Research senkt Ziel für Evotec auf 6 Euro - 'Hold' (dpa-AFX) | |
22.07.25 |
Schwacher Handel in Frankfurt: TecDAX gibt nach (finanzen.at) | |
22.07.25 |
MDAX-Handel aktuell: MDAX leichter (finanzen.at) | |
22.07.25 |
XETRA-Handel MDAX verbucht zum Start des Dienstagshandels Verluste (finanzen.at) | |
22.07.25 |
ANALYSE-FLASH: RBC belässt Evotec auf 'Outperform' - Ziel 11,90 Euro (dpa-AFX) |
Analysen zu EVOTEC SEmehr Analysen
22.07.25 | EVOTEC Hold | Deutsche Bank AG | |
22.07.25 | EVOTEC Outperform | RBC Capital Markets | |
21.07.25 | EVOTEC Outperform | RBC Capital Markets | |
09.07.25 | EVOTEC Hold | Deutsche Bank AG | |
26.06.25 | EVOTEC Buy | Warburg Research |
Aktien in diesem Artikel
EVOTEC SE | 6,22 | -1,24% |
|